Thrombospondin-4 as potential cerebrospinal fluid biomarker for therapy response in pediatric spinal muscular atrophy

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: Thrombospondin-4 as potential cerebrospinal fluid biomarker for therapy response in pediatric spinal muscular atrophy ; volume:271 ; number:10 ; day:6 ; month:9 ; year:2024 ; pages:7000-7011 ; date:10.2024
Journal of neurology ; 271, Heft 10 (6.9.2024), 7000-7011, 10.2024

Creator: Dobelmann, Vera
Roos, Andreas
Hentschel, Andreas
Della Marina, Adela
Leo, Markus
Schmitt, Linda-Isabell
Maggi, Lorenzo
Schara-Schmidt, Ulrike
Hagenacker, Tim
Ruck, Tobias
Kölbel, Heike

Contributor: SpringerLink (Online service)

DOI: 10.1007/s00415-024-12670-0

URN: urn:nbn:de:101:1-2412192155395.025009168158

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:29 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Dobelmann, Vera
Roos, Andreas
Hentschel, Andreas
Della Marina, Adela
Leo, Markus
Schmitt, Linda-Isabell
Maggi, Lorenzo
Schara-Schmidt, Ulrike
Hagenacker, Tim
Ruck, Tobias
Kölbel, Heike
SpringerLink (Online service)

Other Objects (12)

Spinal muscular atrophy

Glial fibrillary acidic protein in cerebrospinal fluid of patients with spinal muscular atrophy

Dysregulation of cerebrospinal fluid metabolism profiles in spinal muscular atrophy patients: a case control study

Routine cerebrospinal fluid (CSF) parameters in patients with spinal muscular atrophy (SMA) treated with nusinersen

Muscle contractility in spinobulbar muscular atrophy

Cathepsin D as biomarker in CSF of nusinersen‐treated patients with spinal muscular atrophy

Neurofilament light protein as a biomarker for spinal muscular atrophy: a review and reference ranges

Very severe spinal muscular atrophy (Type 0)

A cross-sectional and longitudinal evaluation of serum creatinine as a biomarker in spinal muscular atrophy

Disease burden of spinal muscular atrophy in Germany

Choosing Life with Spinal Muscular Atrophy Type 1

Therapeutic advances in 5q-linked spinal muscular atrophy

Spinal muscular atrophy

Glial fibrillary acidic protein in cerebrospinal fluid of patients with spinal muscular atrophy

Dysregulation of cerebrospinal fluid metabolism profiles in spinal muscular atrophy patients: a case control study

Routine cerebrospinal fluid (CSF) parameters in patients with spinal muscular atrophy (SMA) treated with nusinersen

Muscle contractility in spinobulbar muscular atrophy

Cathepsin D as biomarker in CSF of nusinersen‐treated patients with spinal muscular atrophy

Neurofilament light protein as a biomarker for spinal muscular atrophy: a review and reference ranges

Very severe spinal muscular atrophy (Type 0)

A cross-sectional and longitudinal evaluation of serum creatinine as a biomarker in spinal muscular atrophy

Disease burden of spinal muscular atrophy in Germany

Choosing Life with Spinal Muscular Atrophy Type 1

Therapeutic advances in 5q-linked spinal muscular atrophy

Spinal muscular atrophy

Glial fibrillary acidic protein in cerebrospinal fluid of patients with spinal muscular atrophy

Dysregulation of cerebrospinal fluid metabolism profiles in spinal muscular atrophy patients: a case control study

Routine cerebrospinal fluid (CSF) parameters in patients with spinal muscular atrophy (SMA) treated with nusinersen

Muscle contractility in spinobulbar muscular atrophy

Cathepsin D as biomarker in CSF of nusinersen‐treated patients with spinal muscular atrophy

Neurofilament light protein as a biomarker for spinal muscular atrophy: a review and reference ranges

Very severe spinal muscular atrophy (Type 0)

A cross-sectional and longitudinal evaluation of serum creatinine as a biomarker in spinal muscular atrophy

Disease burden of spinal muscular atrophy in Germany

Choosing Life with Spinal Muscular Atrophy Type 1

Therapeutic advances in 5q-linked spinal muscular atrophy

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Thrombospondin-4 as potential cerebrospinal fluid biomarker for therapy response in pediatric spinal muscular atrophy

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Spinal muscular atrophy

Glial fibrillary acidic protein in cerebrospinal fluid of patients with spinal muscular atrophy

Dysregulation of cerebrospinal fluid metabolism profiles in spinal muscular atrophy patients: a case control study

Routine cerebrospinal fluid (CSF) parameters in patients with spinal muscular atrophy (SMA) treated with nusinersen

Muscle contractility in spinobulbar muscular atrophy

Cathepsin D as biomarker in CSF of nusinersen‐treated patients with spinal muscular atrophy

Neurofilament light protein as a biomarker for spinal muscular atrophy: a review and reference ranges

Very severe spinal muscular atrophy (Type 0)

A cross-sectional and longitudinal evaluation of serum creatinine as a biomarker in spinal muscular atrophy

Disease burden of spinal muscular atrophy in Germany

Choosing Life with Spinal Muscular Atrophy Type 1

Therapeutic advances in 5q-linked spinal muscular atrophy

Spinal muscular atrophy

Glial fibrillary acidic protein in cerebrospinal fluid of patients with spinal muscular atrophy

Dysregulation of cerebrospinal fluid metabolism profiles in spinal muscular atrophy patients: a case control study

Routine cerebrospinal fluid (CSF) parameters in patients with spinal muscular atrophy (SMA) treated with nusinersen

Muscle contractility in spinobulbar muscular atrophy

Cathepsin D as biomarker in CSF of nusinersen‐treated patients with spinal muscular atrophy

Neurofilament light protein as a biomarker for spinal muscular atrophy: a review and reference ranges

Very severe spinal muscular atrophy (Type 0)

A cross-sectional and longitudinal evaluation of serum creatinine as a biomarker in spinal muscular atrophy

Disease burden of spinal muscular atrophy in Germany

Choosing Life with Spinal Muscular Atrophy Type 1

Therapeutic advances in 5q-linked spinal muscular atrophy

Spinal muscular atrophy

Glial fibrillary acidic protein in cerebrospinal fluid of patients with spinal muscular atrophy

Dysregulation of cerebrospinal fluid metabolism profiles in spinal muscular atrophy patients: a case control study

Routine cerebrospinal fluid (CSF) parameters in patients with spinal muscular atrophy (SMA) treated with nusinersen

Muscle contractility in spinobulbar muscular atrophy

Cathepsin D as biomarker in CSF of nusinersen‐treated patients with spinal muscular atrophy

Neurofilament light protein as a biomarker for spinal muscular atrophy: a review and reference ranges

Very severe spinal muscular atrophy (Type 0)

A cross-sectional and longitudinal evaluation of serum creatinine as a biomarker in spinal muscular atrophy

Disease burden of spinal muscular atrophy in Germany

Choosing Life with Spinal Muscular Atrophy Type 1

Therapeutic advances in 5q-linked spinal muscular atrophy

Related objects

Reset password